Boston Scientific - ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients

 

 



FACULTY
 

Boston Scientific - ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients Hemal Gada, MD, MBA
UPMC Pinnacle
Harrisburg, PA
 ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients (Sponsored by Boston Scientific Corporation) Helge Möllmann, MD
St. Johannes Hospital Dortmund
Dortmand, Germany

 
       
ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients (Sponsored by Boston Scientific Corporation) Kendra J. Grubb, MD, MHA
Emory University
Atlanta, GA
ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients (Sponsored by Boston Scientific Corporation) Thomas Pilgrim, MD 
Bern University Hospital 
Berne, Switzerland

 


AGENDA

  • ACURATE neo2: Features and Benefits for Optimized TAVR: Prof. Helge Möllmann
     
  • Lessons from the SCOPE I Study and the ACURATE neo2 Body of Evidence: Prof. Thomas Pilgrim
     
  • Real-World Experience of the LOTUS Edge Valve: Dr. Hemal Gada
     
  • Mitigating a Devastating Outcome: SENTINEL CPS in TAVR: Dr. Kendra Grubb

 


This sponsored message does not reflect the opinion or views of TCTMD or of The Cardiovascular Research Foundation.

In the U.S. the ACURATE neo/ACURATE neo2 Valve System is an investigational device and restricted under federal law to investigational use only. Not available for sale.

ACURATE neo CE mark received 2014. Information for the ACURATE Valve System is for use in countries with applicable product registrations. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.  Information not intended for use in France.

 

This program was supported by: Boston Scientific - ACURATE neo, LOTUS Edge, and Sentinel CPS: Advancing Safety for TAVR Patients